×
About 245 results

ALLMedicine™ Acute Febrile Neutrophilic Dermatosis Center

Research & Reviews  76 results

Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment ...
https://doi.org/10.1172/JCI162137
The Journal of Clinical Investigation; Bhattacharya S, Basu S et. al.

Nov 11th, 2022 - Acute febrile neutrophilic dermatosis (Sweet syndrome) is a potentially fatal multiorgan inflammatory disease characterized by fever, leukocytosis, and a rash with a neutrophilic infiltrate. Disease pathophysiology remains elusive, and current dog...

Atypical presentation of Sweet syndrome with nodular erythema and oral ulcerations prov...
https://doi.org/10.1111/dth.15923
Dermatologic Therapy; Bechtold A, Owczarczyk-Saczonek A

Oct 12th, 2022 - The aim of this article is to present the case of acute febrile neutrophilic dermatosis (Sweet syndrome-SS) after Ad26.COV2.S vaccination against SARS-CoV-2. To the best of our knowledge, this is the second case of SS provoked by this specific vac...

Myeloid Neoplasm Masquerading as Hypereosinophilia and Sweet Syndrome
https://www.mdedge.com/fedprac/avaho/article/257508/hematology/myeloid-neoplasm-masquerading-hypereosinophilia-and-sweet
Oday Elmanaseer, Amin Azem, Syed Mehdi

Aug 31st, 2022 - Introduction Hypereosinophilia can be seen in many medical conditions, including myeloproliferative disorders, and can lead to serious complications if untreated. Sweet syndrome is a rare and painful cutaneous inflammatory condition that has been.

Myeloproliferative Disease
http://emedicine.medscape.com/article/204714-overview

Aug 31st, 2022 - Practice Essentials Myeloproliferative diseases are a heterogeneous group of disorders characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. The peripheral smear below ...

Myeloproliferative Disease
https://emedicine.medscape.com/article/204714-overview

Aug 31st, 2022 - Practice Essentials Myeloproliferative diseases are a heterogeneous group of disorders characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. The peripheral smear below ...

see more →

Drugs  4 results see all →

News  15 results

Cracking the “MGUS” Code Reveals Monoclonal Gammopathy of Clinical Significance:
https://www.onclive.com/view/cracking-the-mgus-code-reveals-monoclonal-gammopathy-of-clinical-significance-

Nov 1st, 2022 - When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment. On initial patient consultation, gathering a detailed patient history and thorough physical exam can catch clinically signifi...

Myeloid Neoplasm Masquerading as Hypereosinophilia and Sweet Syndrome
https://www.mdedge.com/fedprac/avaho/article/257508/hematology/myeloid-neoplasm-masquerading-hypereosinophilia-and-sweet
Oday Elmanaseer, Amin Azem, Syed Mehdi

Aug 31st, 2022 - Introduction Hypereosinophilia can be seen in many medical conditions, including myeloproliferative disorders, and can lead to serious complications if untreated. Sweet syndrome is a rare and painful cutaneous inflammatory condition that has been.

Tender, Diffuse, Edematous, and Erythematous Papules on the Face, Neck, Chest, and Extremities
https://www.mdedge.com/dermatology/article/238571/dermatopathology/tender-diffuse-edematous-and-erythematous-papules-face
Christine Schleich, MD, Tammie Ferringer, MD

Apr 13th, 2021 - The Diagnosis: Sweet Syndrome Sweet syndrome, alternatively known as acute febrile neutrophilic dermatosis, typically presents with variably tender, erythematous papules, plaques, or nodules in middle-aged adults. 1 Systemic symptoms such as fever,.

FDA Issues Complete Response Letter for Quizartinib in AML
https://www.onclive.com/view/fda-issues-complete-response-letter-for-quizartinib-in-aml

Dec 4th, 2020 - Antoine Yver, MD The FDA has issued a complete response letter to Daiichi Sankyo informing the company that its new drug application (NDA) would not be approved for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD...

FDA Panel Votes Against Quizartinib for AML
https://www.onclive.com/view/fda-panel-votes-against-quizartinib-approval-for-aml

Dec 4th, 2020 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 8-3 against approving a new drug application (NDA) for quizartinib for adult patients with relapsed/refractory FLT3-ITD—positive acute myeloid leukemia (AML). The FDA is now scheduled to m...

see more →

Patient Education  3 results see all →